TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10456450

Group type: EXPERIMENTAL
Intervention: Dermatan sulphate (600 mg intramuscularly on the second day before surgery, then 300 mg once daily)
Number of subjects: 842

Group type: COMPARATOR
Intervention: Calcium heparin (5,000 IU subcutaneously t.i.d., starting 2 hours before operation)
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: Dermatan sulphate
Number of subjects: 842

Group type: COMPARATOR
Intervention: Calcium heparin
Number of subjects: 842
Study: 9407751

Group type: EXPERIMENTAL
Intervention: High intensity exercise (>= 75% maximum heart rate)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Low intensity exercise (<= 60% maximum heart rate)
Number of subjects: 42
Study: 1741875

Group type: EXPERIMENTAL
Intervention: 1 mg/kg secobarbital (S)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 2 micrograms/kg fentanyl (F)
Number of subjects: 29
Study: 6284564

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2 g die i.v. for 7 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Gentamicin 240 mg die i.m. for 7 days
Number of subjects: 40
Study: 31663156

Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication review with patient involvement (questionnaire and telephone call with pharmacist)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 75
Study: 30706382

Group type: EXPERIMENTAL
Intervention: U‐HRCT
Number of subjects: 10

Group type: COMPARATOR
Intervention: C‐CT
Number of subjects: 10
Study: 27453302

Group type: EXPERIMENTAL
Intervention: Systemic targeted- and immunotherapy (e.g., ipilimumab, pembrolizumab, nivolumab, vemurafenib, dabrafenib plus trametinib)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interferon-2b
Number of subjects: 0
Study: 26845668

Group type: EXPERIMENTAL
Intervention: Body-weight suspension training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Treadmill training
Number of subjects: 20
Study: 24833694

Group type: EXPERIMENTAL
Intervention: Deferred consent process
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Tailored explanation of EcLiPSE
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Safety of interventions under investigation
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Recruitment discussion timing
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Individualised approaches for bereaved parents
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Clear written information
Number of subjects: 17
Study: 23046985

Group type: EXPERIMENTAL
Intervention: Piece‐rate pay for performance (P4P) program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Claims analysis for younger adults
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Survey study
Number of subjects: 0
Study: 19897678

Group type: EXPERIMENTAL
Intervention: T(4) therapy
Number of subjects: 20
Study: 18377908

Group type: EXPERIMENTAL
Intervention: Overhead ceiling lifts
Number of subjects: 0
Study: 16153532

Group type: EXPERIMENTAL
Intervention: 3-dimensional echocardiography (3DE)
Number of subjects: 100

Group type: COMPARATOR
Intervention: M-mode echocardiography
Number of subjects: 100

Group type: COMPARATOR
Intervention: 2-dimensional echocardiography (LA planimetry)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 2-dimensional echocardiography (prolate ellipsoid)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 2-dimensional echocardiography (area-length)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 2-dimensional echocardiography (Simpson's biplane)
Number of subjects: 100
Study: 12109639

Group type: EXPERIMENTAL
Intervention: Combination of abciximab in full doses and reteplase in half doses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reteplase in full doses
Number of subjects: 0
Study: 10403324

Group type: EXPERIMENTAL
Intervention: Six-dose regimen of artemether-lumefantrine (480 mg artemether and 2880 mg lumefantrine)
Number of subjects: 359

Group type: COMPARATOR
Intervention: Four-dose regimen of artemether-lumefantrine (320 mg artemether and 1920 mg lumefantrine)
Number of subjects: 359
Study: 7674841

Group type: EXPERIMENTAL
Intervention: Lymphoblastoid human interferon alpha with prednisolone pretreatment (16 cases)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Lymphoblastoid human interferon alpha without prednisolone pretreatment (19 cases)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Lymphoblastoid human interferon alpha with or without prednisolone pretreatment
Number of subjects: 35
Study: 1974510

Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg/o.d.)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Nitrendipine (20 mg/o.d.)
Number of subjects: 81
Study: 6155762

Group type: EXPERIMENTAL
Intervention: H1 + H2-receptor antagonists (dimethypyrindene and cimetidine)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Haemaccel (control)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Cimetidine alone
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Cimetidine plus chlorpheniramine
Number of subjects: 600
Study: 31478283

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with a 660-nm diode laser (25 mW, fluence: 19.23 J/cm2) for three sessions
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sham laser (control)
Number of subjects: 8
Study: 27834567

Group type: EXPERIMENTAL
Intervention: Bone Power
Number of subjects: 866

Group type: EXPERIMENTAL
Intervention: Bone Power Plus
Number of subjects: 866

Group type: COMPARATOR
Intervention: Control
Number of subjects: 866
Study: 26683053

Group type: EXPERIMENTAL
Intervention: Peer assessment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no peer assessment)
Number of subjects: 0
Study: 23005338

Group type: EXPERIMENTAL
Intervention: Stress (Trier Social Stress Test; TSST)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Non-stressful control condition
Number of subjects: 38
Study: 21107435

Group type: EXPERIMENTAL
Intervention: OM/HCTZ 40/25 mg
Number of subjects: 1172

Group type: EXPERIMENTAL
Intervention: OM/HCTZ 40/12.5 mg
Number of subjects: 1172

Group type: EXPERIMENTAL
Intervention: OM/HCTZ 20/12.5 mg
Number of subjects: 1172

Group type: COMPARATOR
Intervention: OM 40 mg
Number of subjects: 1172
Study: 18977314

Group type: EXPERIMENTAL
Intervention: Intervention group (32 primary care practices)
Number of subjects: 56000

Group type: COMPARATOR
Intervention: Control group (32 primary care practices)
Number of subjects: 56000
Study: 18069643

Group type: EXPERIMENTAL
Intervention: Monolayer wide-edge continuous suture anastomosis with absorbable suture
Number of subjects: 936

Group type: COMPARATOR
Intervention: Regular interrupted suture anastomosis with silk thread
Number of subjects: 936
Study: 15084199

Group type: EXPERIMENTAL
Intervention: Direct hemoperfusion with a beta2-microglobulin adsorption column (Lixelle)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no pre-adsorption)
Number of subjects: 22
Study: 11744588

Group type: EXPERIMENTAL
Intervention: Planned Cesarean section at ≥38 weeks' gestation
Number of subjects: 2088

Group type: COMPARATOR
Intervention: Planned vaginal birth by spontaneous labour unless an indication for induction or Cesarean section developed
Number of subjects: 2088
Study: 9542676

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate emollient 0.05% twice daily (n = 41)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Emollient vehicle twice daily (n = 40)
Number of subjects: 81
Study: 8001065

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel (1% applied 4 times a year, 0.7 ml applied interdentally)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo gel (applied 4 times a year, 0.7 ml applied interdentally)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 117
Study: 2086824

Group type: EXPERIMENTAL
Intervention: CEMT-PI-L (250 mg, 2 times a day)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: CEMT-PI-H (500 mg, 2 times a day)
Number of subjects: 103

Group type: COMPARATOR
Intervention: CCL (500 mg, 3 times a day)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: CEMT-PI-L
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: CEMT-PI-H
Number of subjects: 103

Group type: COMPARATOR
Intervention: CCL
Number of subjects: 103
Study: 146628

Group type: EXPERIMENTAL
Intervention: Topical acne cream containing triclosan
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Topical acne cream containing triclosan plus propylene phenoxetol
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (formula without antibacterials)
Number of subjects: 3
Study: 31684758

Group type: EXPERIMENTAL
Intervention: Walking group (n = 18), structured, 12-week, progressive walking program 5 days/week for 12 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Comparison group (n = 15), usual activities
Number of subjects: 33
Study: 31500505

Group type: EXPERIMENTAL
Intervention: Movement quality-focused training (MQ)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Traditional resistance training (TRAD)
Number of subjects: 46
Study: 27874023

Group type: COMPARATOR
Intervention: MAAT/placebo
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: MAAT/MPH
Number of subjects: 71
Study: 25468954

Group type: EXPERIMENTAL
Intervention: Methimazole (MMI) treatment with titration regimen, reduced to 2.5 mg daily after about 5 months, discontinued after 5 months (Group 1)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Methimazole (MMI) treatment with titration regimen, reduced to 2.5 mg every other day after 5 months, discontinued after a further 5 months (Group 2)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Overall treatment with antithyroid drugs (ATD)
Number of subjects: 128
Study: 23671210

Group type: EXPERIMENTAL
Intervention: Artiste Assisted Injection System
Number of subjects: 52

Group type: COMPARATOR
Intervention: Manual delivery of dermal fillers
Number of subjects: 52
Study: 20799296

Group type: EXPERIMENTAL
Intervention: Laparoscopic colectomy
Number of subjects: 122

Group type: COMPARATOR
Intervention: Open colectomy
Number of subjects: 122
Study: 18543095

Group type: EXPERIMENTAL
Intervention: SABT intervention with manager training
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: SABT intervention with combined peer/manager influence
Number of subjects: 980

Group type: COMPARATOR
Intervention: Usual care (control condition)
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: SABT intervention (all types)
Number of subjects: 980
Study: 18042885

Group type: EXPERIMENTAL
Intervention: COX-2 selective inhibitors (e.g., rofecoxib, celecoxib)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonselective NSAIDs (e.g., diclofenac, naproxen)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14742178

Group type: EXPERIMENTAL
Intervention: Distance method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Display-size method combined with zero-slope criterion
Number of subjects: 0
Study: 11890578

Group type: EXPERIMENTAL
Intervention: 12-week task-specific resistance-training intervention (training in bed- and chair-rise subtasks, such as sliding forward to the edge of a chair with the addition of weights)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: 12-week task-specific resistance-training intervention
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control flexibility intervention
Number of subjects: 161
Study: 9425911

Group type: EXPERIMENTAL
Intervention: Variceal pressure (VP) measurement
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: NIEC score + VP
Number of subjects: 87
Study: 7843592

Group type: EXPERIMENTAL
Intervention: l-moprolol
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: dipivefrin
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combination of l-moprolol and dipivefrin
Number of subjects: 27
Study: 3049116

Group type: EXPERIMENTAL
Intervention: Transfer factor (TF) administered to 22 patients with Hodgkin's disease.
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo administered to 25 patients with Hodgkin's disease (control group).
Number of subjects: 47
Study: 31219281

Group type: EXPERIMENTAL
Intervention: STIC Initial Scales - Individual Problems and Strengths (IPS)
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: STIC Initial Scales - Relationship with Partner (RWP)
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: STIC Initial Scales - Family/Household (FH)
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: STIC Initial Scales - Child Problems and Strengths (CPS)
Number of subjects: 583
Study: 27744492

Group type: EXPERIMENTAL
Intervention: Laser acupuncture (group B)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Desmopressin acetate (group A)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Combination of laser acupuncture and desmopressin (group C)
Number of subjects: 45
Study: 25066831

Group type: EXPERIMENTAL
Intervention: Water immersion for 30 min a day for five consecutive days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (unexposed forearm)
Number of subjects: 20
Study: 23595003

Group type: EXPERIMENTAL
Intervention: 50 μg/d (2000 IU/d, analysed dose 70 μg/d)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 250 μg/week (10 000 IU/week, analysed dose 331 μg/week)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 1250 μg/week (50 000 IU/week, analysed dose 1544 μg/week) followed by 1250 μg/month
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 21636116

Group type: EXPERIMENTAL
Intervention: omalizumab (75-375 mg, subcutaneously once every 2 or 4 weeks for 24 weeks)
Number of subjects: 49

Group type: COMPARATOR
Intervention: placebo (subcutaneously once every 2 or 4 weeks for 24 weeks)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: omalizumab
Number of subjects: 49

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 49
Study: 19771409

Group type: EXPERIMENTAL
Intervention: Nasopharyngeal CPAP with open nostril
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nasopharyngeal CPAP with occluded nostril
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nasopharyngeal CPAP with closed mouth
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nasopharyngeal CPAP with open mouth
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nasopharyngeal CPAP with leaks <20%
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nasopharyngeal CPAP with leaks between 20 and 69%
Number of subjects: 32
Study: 16966225

Group type: EXPERIMENTAL
Intervention: Active abuse during pregnancy
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Chaos, instability, and lack of resources
Number of subjects: 35
Study: 15178174

Group type: EXPERIMENTAL
Intervention: Prism adaptation (PA)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Neutral lenses (Control)
Number of subjects: 2
Study: 11268375

Group type: COMPARATOR
Intervention: Vaccination with live attenuated rubella virus
Number of subjects: 0

Group type: COMPARATOR
Intervention: LPS administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic treatment with antidepressants (imipramine or fluoxetine)
Number of subjects: 0
Study: 9351765

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel
Number of subjects: 443

Group type: COMPARATOR
Intervention: Hygroscopic dilation
Number of subjects: 443
Study: 8222498

Group type: EXPERIMENTAL
Intervention: 100 mg ketoprofen
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 50 mg ketoprofen
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 650 mg acetaminophen plus 10 mg oxycodone hydrochloride
Number of subjects: 240

Group type: COMPARATOR
Intervention: 650 mg acetaminophen
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 3952172

Group type: EXPERIMENTAL
Intervention: Fixed-interval 90-sec schedule
Number of subjects: 66

Group type: COMPARATOR
Intervention: Random-interval 90-sec schedule
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study: 29989486

Group type: EXPERIMENTAL
Intervention: 2,000 steps/day (STEP group)
Number of subjects: 17

Group type: COMPARATOR
Intervention: No intervention (CON group)
Number of subjects: 17
Study: 30340708

Group type: EXPERIMENTAL
Intervention: Eye examinations performed in shelters for children and AYFM
Number of subjects: 49
Study: 27852246

Group type: EXPERIMENTAL
Intervention: Central hole ICL
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional ICL
Number of subjects: 22
Study: 24824288

Group type: EXPERIMENTAL
Intervention: Enhanced diet (higher amounts of energy, protein, lipids, vitamin A, arachidonic acid, and docosahexaenoic acid)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: All infants (both groups)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Small for gestational age (SGA) infants
Number of subjects: 48
Study: 23516055

Group type: EXPERIMENTAL
Intervention: Vibrotactile feedback from an array of eight stimulators on the forearm
Number of subjects: 10

Group type: COMPARATOR
Intervention: No feedback about the hand opening
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Three levels of distraction (no distraction, counting task, count and subtract task)
Number of subjects: 10
Study: 20345708

Group type: EXPERIMENTAL
Intervention: PAI-749
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (t-PA)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Blocking antibody against PAI-1
Number of subjects: 12
Study: 18544975

Group type: EXPERIMENTAL
Intervention: Low fat diet (diet I)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet (diet II)
Number of subjects: 78
Study: 15882368

Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 60
Study: 12623738

Group type: EXPERIMENTAL
Intervention: High-structure, behaviorally-oriented (HSB) individual counseling
Number of subjects: 143

Group type: COMPARATOR
Intervention: Low-structure, facilitative (LSF) individual counseling
Number of subjects: 143
Study: 10561210

Group type: EXPERIMENTAL
Intervention: Oral medroxyprogesterone acetate 200 mg/d
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Oral medroxyprogesterone acetate 1,000 mg/d
Number of subjects: 299
Study: 8739857

Group type: EXPERIMENTAL
Intervention: anti-CD4 monoclonal antibody/prednisolone
Number of subjects: 12

Group type: COMPARATOR
Intervention: multiple injections of insulin alone
Number of subjects: 12
Study: 1928949

Group type: EXPERIMENTAL
Intervention: Albuterol (2.5 mg) followed by allergen
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo followed by allergen
Number of subjects: 10

Group type: COMPARATOR
Intervention: Albuterol followed by saline
Number of subjects: 10
Study: 6405650

Group type: EXPERIMENTAL
Intervention: Oral disodium cromoglycate (DSCG) 200 mg qid for adults, 100 mg qid for children
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31711168

Group type: EXPERIMENTAL
Intervention: EHR tools plus coaching (coaching group)
Number of subjects: 194

Group type: COMPARATOR
Intervention: EHR tools (tracking group)
Number of subjects: 194
Study: 29570853

Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel
Number of subjects: 262
Study: 26596400

Group type: EXPERIMENTAL
Intervention: Ahmed Glaucoma Valve FP7
Number of subjects: 276

Group type: COMPARATOR
Intervention: Baerveldt Glaucoma Implant BG 101‐350
Number of subjects: 276
Study: 25086831

Group type: EXPERIMENTAL
Intervention: Ocular Response Analyzer (ORA) with Narafilcon A (1‐Day Acuvue True Eye)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ocular Response Analyzer (ORA) with Nelfilcon A (Daily AquaComfort Plus)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Ocular Response Analyzer (ORA) without soft contact lenses
Number of subjects: 28
Study: 21985338

Group type: EXPERIMENTAL
Intervention: Guided imagery with tape
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Guided imagery with perceived happy memory
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (individualized therapy without guided imagery)
Number of subjects: 60
Study: 19616166

Group type: EXPERIMENTAL
Intervention: Educational program consisting of three sessions between the educator and persons with diabetes
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 50
Study: 17196453

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 985

Group type: EXPERIMENTAL
Intervention: Statin therapy with LDL <100 mg/dl
Number of subjects: 985

Group type: EXPERIMENTAL
Intervention: Statin therapy with LDL >=100 mg/dl
Number of subjects: 985

Group type: COMPARATOR
Intervention: No statin therapy (Control)
Number of subjects: 985
Study: 15272394

Group type: EXPERIMENTAL
Intervention: Abacavir
Number of subjects: 111

Group type: COMPARATOR
Intervention: Thymidine analogues
Number of subjects: 111
Study: 12410892

Group type: EXPERIMENTAL
Intervention: Multifocal glasses wearers
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Regular multifocal glasses use
Number of subjects: 156
Study: 9822313

Group type: EXPERIMENTAL
Intervention: 0.5 microg/kg subcutaneous octreotide
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 1.0 microg/kg subcutaneous octreotide
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Subcutaneous octreotide (both doses)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Subcutaneous octreotide
Number of subjects: 23
Study: 8086018

Group type: EXPERIMENTAL
Intervention: Endoscopic carpal tunnel release
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open carpal tunnel release
Number of subjects: 0
Study: 2509186

Group type: EXPERIMENTAL
Intervention: Transdermal intermittent-release nitroglycerin system (10 mg nitroglycerin, daily for eight days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (placebo plaster, daily for eight days)
Number of subjects: 24
Study: 30473202

Group type: EXPERIMENTAL
Intervention: Individual hypnotherapy
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Group hypnotherapy
Number of subjects: 354

Group type: COMPARATOR
Intervention: Educational supportive therapy (control)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Hypnotherapy (both groups combined)
Number of subjects: 354